Pharmacokinetics of isoniazid and rifampin in adults with tuberculosis.

被引：0
|
作者：
Auclair, B
Burman, WJ
Stambaugh, JJ
Berning, SE
Ashkin, D
Peloquin, CA
机构：
[1] Natl Jewish, Denver, CO USA
[2] Denver Publ Hlth, Denver, CO USA
[3] AG Holley Hosp, Lantana, FL USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 1999年 / 159卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：A495 / A495
页数：1
相关论文
共 50 条
  • [1] Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients
    McIlleron, H
    Wash, P
    Burger, A
    Norman, J
    Folb, PI
    Smith, P
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (04) : 1170 - 1177
  • [2] Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients
    Sundell, Jesper
    Bienvenu, Emile
    Birgersson, Sofia
    Abelo, Angela
    Ashton, Michael
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (10)
  • [3] Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
    Menzies, D.
    Adjobimey, M.
    Ruslami, R.
    Trajman, A.
    Sow, O.
    Kim, H.
    Baah, J. Obeng
    Marks, G. B.
    Long, R.
    Hoeppner, V.
    Elwood, K.
    Al-Jahdali, H.
    Gninafon, M.
    Apriani, L.
    Koesoemadinata, R. C.
    Kritski, A.
    Rolla, V.
    Bah, B.
    Camara, A.
    Boakye, I.
    Cook, V. J.
    Goldberg, H.
    Valiquette, C.
    Hornby, K.
    Dion, M. -J.
    Li, P. -Z.
    Hill, P. C.
    Schwartzman, K.
    Benedetti, A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (05): : 440 - 453
  • [4] ISONIAZID-RIFAMPIN REGIMENS FOR TUBERCULOSIS
    FARER, LS
    LONG, MW
    SNIDER, DE
    ANNALS OF INTERNAL MEDICINE, 1981, 95 (04) : 518 - 519
  • [5] TREATMENT OF TUBERCULOSIS WITH ISONIAZID, RIFAMPIN AND PYRAZINAMIDE
    BRANDLI, O
    DREHER, D
    MORGER, D
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1993, 123 (25) : 1300 - 1306
  • [6] STUDIES ON THE EFFECT OF RIFAMPIN ON THE PHARMACOKINETICS OF ISONIAZID AND ITS MAIN METABOLITE, ACETYLHYDRAZINE IN RATS - TO EXPLAIN THE INCIDENCE OF HEPATITIS DURING THE TREATMENT OF TUBERCULOSIS WITH ISONIAZID AND RIFAMPIN
    ZHANG, RL
    LI, D
    CHENG, WB
    WANG, ZY
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (06) : 2295 - 2295
  • [7] ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS
    Egelund, Eric F.
    Isaza, Ramiro
    Alsultan, Abdullah
    Peloquin, Charles A.
    JOURNAL OF ZOO AND WILDLIFE MEDICINE, 2016, 47 (03) : 868 - 871
  • [8] MARKERS OF GUT DYSFUNCTION DO NOT EXPLAIN VARIABILITY IN RIFAMPIN PHARMACOKINETICS IN HIV-ASSOCIATED TUBERCULOSIS.
    Vinnard, C.
    Ravimohan, S.
    Tamuhla, N.
    Ivaturi, V.
    Pasipanodya, J.
    Srivastava, S.
    Modongo, C.
    Zetola, N.
    Weissman, D.
    Gumbo, T.
    Bisson, G. P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S51 - S52
  • [9] AGING AND HEPATOTOXICITY OF ISONIAZID AND RIFAMPIN IN PULMONARY TUBERCULOSIS
    VANDENBRANDE, P
    VANSTEENBERGEN, W
    VERVOORT, G
    DEMEDTS, M
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1995, 152 (05) : 1705 - 1708
  • [10] ISONIAZID-RIFAMPIN REGIMENS FOR TUBERCULOSIS - REPLY
    BUECHNER, HA
    ANNALS OF INTERNAL MEDICINE, 1981, 95 (04) : 519 - 519
12345